Aerie Pharmaceuticals reported $115.29M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Aerie Pharmaceuticals AERI:US $ 115.29M 9.7M
Alimera Sciences ALIM:US $ 17.01M 4.41M
Amarin AMRN:US $ 300.57M 70.11M
Bluebird Bio BLUE:US $ 142.89M 10.1M
Cara Therapeutics CARA:US $ 18.3M 680K
Coherus Biosciences CHRS:US $ 153.75M 11.58M
Endo International Ordinary Shares ENDP:US $ 1376.14M 253.82M
Horizon Pharma HZNP:US $ 825.18M 61.39M
Insmed INSM:US $ 125.25M 9.92M
JAZZ PHA JAZZ:US $ 737.41M 71.89M
Merk MRK:US $ 22316M 1556M
Mirati Therapeutics MRTX:US $ 123.57M 20.09M
Novartis NOVN:VX SF 29807M 401M
Ophthotech OPHT:US $ 19.17M 9.04M
Pacira Pharmaceuticals PCRX:US $ 305.07M 216.04M
Regeneron Pharmaceuticals REGN:US $ 3007.6M 924.9M
Revance Therapeutics RVNC:US $ 71.07M 3.78M
Supernus Pharmaceuticals SUPN:US $ 284.56M 30.82M
Teva Pharmaceutical Industries TEVA:US $ 11613M 586M
Valeant Pharmaceuticals VRX:CN $ 4774M 424M
Zoetis ZTS:US $ 3034M 1237M